← FDA DRUG APPROVALS

FDA ANDA · ANDA077253

FLUCONAZOLE

Sponsor: GLENMARK PHARMS LTD

APPLICATION
ANDA077253
TYPE
ANDA
ORIGINAL APPROVAL
2006-01-25
LATEST ACTION
2023-10-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

FLUCONAZOLEPrescription
FLUCONAZOLE 200MG · TABLET · ORAL
FLUCONAZOLEPrescription
FLUCONAZOLE 100MG · TABLET · ORAL
FLUCONAZOLEPrescription
FLUCONAZOLE 150MG · TABLET · ORAL
FLUCONAZOLEPrescription
FLUCONAZOLE 50MG · TABLET · ORAL

Approval history

2023-10-24Labeling · Supplement 25 · standardAP
2023-07-20Labeling · Supplement 23 · standardAP
2023-07-20Labeling · Supplement 24 · standardAP
2022-07-06Labeling · Supplement 21 · standardAP
2022-07-06Labeling · Supplement 20 · standardAP
2021-10-06Labeling · Supplement 18 · standardAP
2019-06-28Labeling · Supplement 17 · standardAP
2019-06-28Labeling · Supplement 16 · standardAP
2019-06-28Labeling · Supplement 14 · standardAP
2015-03-14Labeling · Supplement 8 · standardAP
2015-03-14Labeling · Supplement 11 · standardAP
2015-03-14Labeling · Supplement 9 · standardAP
2011-12-16Labeling · Supplement 7AP
2011-10-13Labeling · Supplement 6AP
2008-08-28Labeling · Supplement 2AP
2006-01-25OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →